Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018 Apr 30, 2018 04:30PM
Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 25, 2018 01:06PM
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 4, 2018 08:30AM
Portola Pharma (PTLA) Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban Mar 23, 2018 09:09AM
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union Mar 23, 2018 09:06AM
View Older Stories

Mar 12, 2018 12:12PM Portola Pharma (PTLA) Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa in Patients with Life-Threatening Bleeding
Mar 12, 2018 12:12PM Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening Bleeding
Mar 12, 2018 08:30AM Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel
Mar 6, 2018 04:05PM Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
Mar 5, 2018 04:10PM Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet Alfa
Feb 28, 2018 04:05PM Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Feb 20, 2018 05:36PM Portola Pharma (PTLA) Announces CHMP of EMA Communicated Positive Trend Vote on MAA for Andexanet Alfa and Negative Trend Vote for Betrixaban
Feb 20, 2018 04:47PM Portola Pharmaceuticals Announces Positive Trend of Andexxa, Negative Trend for Betrixaban
Feb 15, 2018 04:05PM Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
Jan 23, 2018 05:46AM Portola Pharma (PTLA) Reports Interim Results from Ongoing Phase 3b/4 ANNEXA-4 Trials for Andexanet Alfa
Jan 22, 2018 09:33PM Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
Dec 26, 2017 05:47AM Portola Pharma (PTLA) Reports Update on Biologics License Application (BLA) for AndexXa (andexanet alfa)
Dec 22, 2017 05:23PM Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa)
Dec 22, 2017 08:00AM Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018
Dec 19, 2017 10:37AM Portola Pharma (PTLA) Announces FDA Approval of PAS for Commercial Launch of its Novel Oral Anticoagulant Bevyxxa
Dec 19, 2017 10:35AM U.S. Food and Drug Administration Approves Prior Approval Supplement for Commercial Launch of Portola Pharmaceuticals’ Novel Oral Anticoagulant Bevyxxa® (betrixaban)
Dec 12, 2017 08:33AM Portola Pharma (PTLA) Announces CHMP of EMA Requested Additional Information Related to MAA for Betrixaban
Dec 12, 2017 08:30AM Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for Betrixaban
Nov 30, 2017 08:01AM Portola Pharma (PTLA) to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at ASH
Nov 30, 2017 08:00AM Portola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 22, 2017 05:44AM Portola Pharma (PTLA) Reports Update on Bevyxxa (betrixaban) Commercial Launch
Nov 21, 2017 06:22PM Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch
Nov 7, 2017 08:27AM Portola Pharma (PTLA) Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at AHA
Nov 7, 2017 08:00AM Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017
Nov 6, 2017 04:01PM Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Nov 6, 2017 08:29AM Portola Pharma (PTLA) Names John H. Lawrence, M.D., as SVP and CMO
Nov 6, 2017 08:00AM Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical Officer
Nov 3, 2017 08:00AM Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference
Oct 30, 2017 08:00AM Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 6
Oct 11, 2017 04:05PM Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
Sep 6, 2017 08:00AM Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference
Sep 5, 2017 08:00AM Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch
Sep 1, 2017 06:34PM Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch
Aug 21, 2017 08:00AM Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the European Society of Cardiology (ESC) Congress 2017
Aug 15, 2017 08:03AM Portola Pharma (PTLA) Reports AndexXa (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by FDA
Aug 15, 2017 08:00AM Portola Pharmaceuticals Announces AndexXa® (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Aug 9, 2017 04:25PM Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 3, 2017 05:18PM Portola Pharma (PTLA) Announces Resubmission of BLA for AndexXa
Aug 3, 2017 04:13PM Portola Pharmaceuticals Announces Resubmission of Biologics License Application for AndexXa® (Andexanet Alfa)
Aug 2, 2017 08:00AM Portola Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9
Jul 27, 2017 04:09PM Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 6, 2017 08:00AM Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Com
Jun 23, 2017 01:06PM Portola Pharma (PTLA) Confirms FDA Approval of Bevyxxa
Jun 23, 2017 01:04PM U.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
Jun 15, 2017 08:33AM Portola Pharma (PTLA) Presents Interim Phase 2a Data for Cerdulatinib at ICML
Jun 15, 2017 08:30AM Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma
May 18, 2017 08:00AM Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)
May 9, 2017 08:00AM Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)
May 8, 2017 04:36PM Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 1, 2017 08:00AM Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8
View Older Stories